The Molecular Diagnostics (MDx) Market Forecast 2014-2024 : Opportunities for Leading Companies

世界の分子診断市場:感染症検査、癌検査、血液検査、遺伝子検査

◆タイトル:The Molecular Diagnostics (MDx) Market Forecast 2014-2024 : Opportunities for Leading Companies
◆商品コード:VGAIN4120202
◆調査・発行会社:visiongain
◆発行日:2014年10月
◆ページ数:173
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single user licence(1名使用、1年)GBP1,799 ⇒換算¥269,850見積依頼/購入/質問フォーム
Dept Licence(5名まで共有可、1年)GBP2,999 ⇒換算¥449,850見積依頼/購入/質問フォーム
Site Licence(全社内共有可、PDF制限なし)GBP4,999 ⇒換算¥749,850見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、世界の分子診断市場について調査・分析し、イントロダクション、セグメント別市場分析、地域別市場分析、市場環境分析、専門家の見解、主要企業分析データなどをお届けいたします。

Molecular Diagnostics (MDx) – your guide to technologies, trends and revenues
Where is the molecular diagnostics market heading? Visiongain’s new report gives you revenue predictions for the molecular diagnostics market and its submarkets from 2014, helping you stay ahead.

The 173-page report provides 134 tables, charts, and graphs. Discover the growing trends of this industry. In particular, our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, drivers and restraints, and revenue predictions.

Besides revenue forecasts to 2024, this report provides you with market shares, business outlooks, qualitative analyses (including SWOT and Porter’s Fiver Forces Analysis), company profiles and commercial developments. Also, read the full transcript of an exclusive expert opinion interview informing you about prospects for investments and sales from:
- Mike Nugent, Worldwide Market Segment Leader BD MAX, BD Diagnostics
Many opportunities exist in the fast-growing molecular diagnostics market. Our new study shows you the most promising parts of the market, helping you stay ahead.

Discover sales predictions for the overall IVD and MDx market
See how the molecular diagnostics market is forecast to perform compared to the rest of the IVD market up to 2024. The report also gives the market size of the following IVD segments in 2013:
• Clinical Chemistry
• Immunochemistry
• Point of-care testing (including SMBG)
• Molecular Diagnostics
• Clinical Microbiology
• Haematology/ Haemostasis.
This will give you insight into the current market position of the MDx market and how its market share in the IVD market is set to change over the forecast period.

See revenue forecasts for leading molecular diagnostics submarkets from 2014 to 2024
Along with prediction of the overall world market to 2024, our report shows you revenue forecasting for the five leading submarkets at world level:
• Infectious disease testing market forecast 2014-2024
• Oncology testing market forecast 2014-2024
• Blood screening market forecast 2014-2024
• Genetic testing market forecast 2014-2024
• Tissue (HLA) typing market forecast 2014-2024
Our new study discusses what stimulates and restrains this market. The analysis helps you identify market potential and find ways for your business to develop.

What are the prospects for the leading regions and countries?
Developments worldwide will influence the market, especially fast-rising demand in emerging countries.
Our analyses show you individual revenue forecasts to 2024 for 14 national markets:
• US
• Japan
• Germany
• France
• UK
• Italy
• Spain
• Rest of Europe
• China
• Brazil
• Russia
• India
• South Korea
• Mexico
• Rest of the World

There you find potential. Large companies and specialty diagnostics firms face many opportunities. Our study explains, assessing developments to help your work. Our analysis show sustained growth, particularly for the BRIC nations of Brazil, Russia, India, and China.

Leading companies and potential for market growth
Our new study predicts the world market for molecular diagnostics will reach $6.13bn in 2014 and will continue to grow rapidly. Expanding MDx test menus and increasing patient and physician adoption are driving the growth of this market.

Our work shows you what organisations hold greatest potential. See profiles of 7 leading companies:
• Roche Diagnostics
• Gen-Probe Hologic
• Qiagen
• Becton, Dickinson & Company
• bioMérieux
• Cepheid
• Agilent

【レポートの目次】

1. Report Overview
1.1 The Molecular Diagnostics Market Overview
1.2 Molecular Diagnostics Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain

2. Introduction to Molecular Diagnostics
2.1 What are In Vitro Diagnostic (IVD) Tests?
2.2 Classifying In Vitro Diagnostics
2.2.1 FDA Classifications
2.2.2 IVD Classification in Australia
2.2.3 The EC (European Commission) Classification
2.3 IVD Submarkets
2.3.1 Clinical Chemistry
2.3.2 Immunochemistry
2.3.3 Point-of-care Testing (Including Self-monitoring Blood Glucose Tests)
2.3.4 Molecular Diagnostics
2.3.4.1 Infectious Disease Testing
2.3.4.2 Oncology Testing
2.3.4.3 Blood Screening
2.3.4.4 Genetic Testing
2.3.4.5 Tissue Typing (HLA Testing)
2.3.5 Clinical Microbiology
2.3.6 Haematology/ Haemostasis
2.4 Regulation of the IVD and MDx Market
2.4.1 FDA and CLIA Regulation of IVD and MDx Tests
2.4.1.1 Regulation of IVD/MDx Tests in the EU: The EC (European Commission) Classification
2.4.2 Top Ten Challenges in Regulation for In-Vitro Diagnostics
2.4.2.1 Challenges in Regulations of MDx tests
2.5 Device Excise Tax: A Threat to the Diagnostics Manufacturers

3. The Molecular Diagnostics Segment Within the In Vitro Diagnostics Market, 2014-2024
3.1 Molecular Diagnostics in the IVD Market, 2013
3.2 Sales Forecast for the Global IVD Market 2014-2024
3.3 Molecular Diagnostics Gaining Greater Share of the IVD Market

4. The Molecular Diagnostics Market by Sectors, 2014-2024
4.1 The Molecular Diagnostic Market by Sectors, 2013
4.2 The Molecular Diagnostic Market by Sectors 2014-2024
4.2.1 Market Shares of the Molecular Diagnostics Sectors 2014-2024
4.3 The Infectious Disease Testing Market 2014-2024
4.3.1 Breakdown of the MDx Infectious Disease Testing Market by Disease, 2013
4.3.1.1 HPV Testing
4.3.1.2 CT/NT
4.3.1.3 HIV
4.3.1.4 Hepatitis C (HCV)
4.3.1.5 MRSA/ C. diff
4.4 The Oncology Testing Market, 2014-2024
4.4.1 Targeted Therapies: A Major Driver of the Oncology Testing Market
4.4.2 Molecular Diagnostics: Currently Concentrated on a Few Cancer Indications
4.4.2.1 Breast Cancer
4.4.2.2 Prostate Cancer
4.4.2.2.1 Pipeline Biomarker
4.4.2.2.1.1 TMPRSS2-ERG (OriGene)
4.4.2.2.1.2 PTEN
4.4.2.3 Colorectal Cancer
4.5 The Blood Screening Market 2014-2024
4.5.1 Grifols’ Acquisition of Novartis’s Blood Screening Unit
4.5.2 Leading Blood Screening Test Products
4.5.2.1 Cobas s 201 System (Roche Molecular)
4.5.2.2 Procleix Assays (Grifols)
4.6 The Genetic Testing Market 2014-2024
4.6.1 Genetic Testing by Clinical Impact Area
4.6.2 Genetic Testing: Potentially Many More Disease Indications
4.6.3 Cystic fibrosis
4.6.4 Factor V Leiden and Factor II Thrombophilia
4.6.5 Inflammatory diseases
4.6.5.1 Alzheimer’s Disease (AD)
4.6.5.2 Rheumatoid Arthritis
4.6.5.2.1 Vectra®DA (Crescendo Bioscience)
4.6.5.2.2 Quest Diagnostics: Biomarker Study
4.6.5.3 Rare Diseases
4.7 The Tissue Typing (HLA) Market 2014-2024
4.7.1 Tissue Typing: Next Generation Sequencing

5. The Leading Molecular Diagnostics National Markets, 2014-2024
5.1 Regional Breakdown of the Global MDx Market, 2013
5.2 The Global MDx Market Forecast 2014-2024
5.3 The Regional Market Shares of the MDx Market, 2014-2024
5.4 The US MDx Market 2013: Representing More than Half of the Global Market
5.4.1 The US MDx Market Forecast 2014-2024
5.4.1.1 United States: Diagnostic Reimbursement
5.5 The European MDx Markets Forecast, 2014-2024
5.5.1 Changes in the Shares of the Leading European Markets, 2014-2024
5.5.2 The German MDx Market Forecast 2014-2024
5.5.3 The French MDx Market Forecast 2014-2024
5.5.4 The Italian MDx Market Forecast 2014-2024
5.5.5 The Spanish MDx Market Forecast 2014-2024
5.5.6 The UK MDx Market Forecast 2014-2024
5.5.7 The Other European MDx Markets Forecast 2014-2024
5.6 The Japanese MDx Market Forecast 2014-2024
5.7 The Chinese MDx Market Forecast 2014-2024
5.7.1 China: Increasing Cancer Burden
5.8 The Brazilian MDx Market Forecast 2014-2024
5.9 The Russian MDx Market Forecast 2014-2024
5.10 The Indian MDx Market Forecast 2014-2024
5.10.1 India: Expansion of Healthcare Provisions
5.11 The South Korean MDx Market Forecast 2014-2024
5.12 The Mexican MDx Market Forecast 2014-2024
5.13 The Rest of the World Market Forecast 2014-2024

6. The Leading Companies in the Molecular Diagnostics Market, 2014-2024
6.1 Roche Diagnostics
6.1.1 Roche: Global Presence
6.1.2 Roche Diagnostics, 2014-2024
6.1.3 Roche Diagnostics Business Performance within the IVD Market, 2013
6.1.3.1 Molecular Diagnostics Sales Performance, 2013
6.1.3.2 Molecular Diagnostic Sales by Region, 2013
6.1.4 Roche Diagnostics: MDx Product Launches and Indication Expansion, 2014
6.1.4.1 Roche Diagnostics: Product Launch Plans, 2014
6.1.4.2 Roche: Recent M&A Activity and Strategic Partnerships
6.2 Hologic Gen-Probe
6.2.1 Hologic Recent Sales Performance by Business Segment, 2013
6.2.2 Hologic Molecular Diagnostics: Product Portfolio
6.2.3 Product Pipeline: Infectious Disease Focus, but Prostate Cancer Diagnostics Shows Promise
6.2.4 Changes in Molecular Diagnostic Operations Structuring
6.3 Qiagen
6.3.1 Sales and Recent Performance Analysis, 2013
6.3.2 Qiagen Sales by Region, 2013
6.3.3 Qiagen Sales by Segment, 2013
6.3.4 Qiagen: Molecular Diagnostics
6.3.5 Molecular Diagnostics: Product Expansion
6.3.5.1 QIASymphony
6.3.5.2 QuantiFERON-TB Gold: Expansion into China
6.3.5.3 Personalised Healthcare: Collaborative Efforts
6.3.5.4 Bioinformatics: Software Company Acquisitions
6.4 Becton, Dickinson & Company
6.4.1 Sales and Financial Performance, 2013
6.4.2 Sales and Financial Performance by Region, 2013
6.4.3 Becton Dickinson Diagnostics Sales and Financial Performance, 2012-2013
6.4.4 BD Diagnostics: Product Portfolio
6.4.5 BD Diagnostics: Mergers and Acquisitions
6.5 BioMérieux
6.5.1 Sales and Recent Performance Analysis, 2010-2013
6.5.2 Sales by Region, 2013
6.5.3 Sales by Technology, 2013
6.5.4 Molecular Diagnostics: Product Portfolio
6.5.5 Companion Diagnostics: Collaboration with GSK
6.5.6 Mergers and Acquisitions
6.5.7 bioTheranostics: Subsidiary for Oncology Diagnostics
6.6 Cepheid
6.6.1 Sales and Recent Performance Analysis, 2010-2013
6.6.2 Sales by Industry Segment, 2012-2013
6.6.3 Sales by Region, 2012-2013
6.6.4 Cepheid: Product Line
6.6.5 Cepheid: Business strategy
6.7 Agilent (Dako)
6.7.1 Sales and Recent Performance Analysis, 2013
6.7.2 Sales Performance by Business Segment, 2013
6.7.3 Agilent: Strong Player in Next Generation Sequencing

7. Qualitative Analysis of the MDx Market, 2014-2024
7.1 MDx market: Drivers and Restraints
7.2 SWOT Analysis of the MDx Market, 2014-2024
7.3 Strength
7.3.1 Patient Demographics
7.3.2 Increased Awareness
7.3.3 High Growth in Oncology Molecular Diagnostics
7.3.4 Increasing Laboratory Test Menus
7.3.5 Personalised Medicine: Optimising Treatment Outcomes
7.4 Weaknesses
7.4.1 Lack of Clear Regulatory Guidelines for Molecular Diagnostics
7.4.2 Reimbursement Challenges for Molecular Diagnostic Companies
7.4.2.1 Consolidation of Healthcare Systems Increases Pricing Pressure
7.4.2.2 Reimbursement Uncertainty Discourages Capital Investment
7.4.3 MDx: An Expensive, but Undervalued Diagnostic Tool
7.5 Opportunities
7.5.1 Next-generation Sequencing
7.5.2 Emerging Markets
7.5.3 The Emergence of New Microorganisms
7.6 Threats
7.6.1 US Medical Device Excise Tax
7.6.2 Gene Patents: Controversial Ruling
7.7 Porter’s Five Forces Analysis of the MDx Market
7.7.1 Rivalry Among Competitors [High]
7.7.2 Threat of New Entrants [Medium]
7.7.3 Power of Suppliers [Medium]
7.7.4 Power of Buyers [High]
7.7.5 Threat of Substitutes [High]

8. Expert Opinions
8.1 Mike Nugent, Worldwide Market Segment Leader BD MAX, BD Diagnostics
8.1.1 Becton Dickinson’s Leadership in Infectious Disease Molecular Diagnostics
8.1.2 BD MAX System: Becton Diagnostics Leading Product
8.1.3 The Changing Landscape of the MDx Industry
8.1.4 Cost: A Deterrent of MDx Use

9. Conclusions
9.1 The Molecular Diagnostics Market: Growing Market Share
9.2 Molecular Diagnostics: Oncology Testing Market Growth
9.3 Commercial Drivers of the Molecular Diagnostics Market
9.4 Commercial Restraints of the Molecular Diagnostics Market
9.5 Emerging Markets
9.6 Concluding Remarks

List of Tables
Table 2.1 Advantages and Disadvantages of POC Diagnostics, 2014
Table 3.1 World IVD Market: Revenues ($bn) and Market Share (%) by Segment, 2013
Table 3.2 World IVD Market Forecast: Revenue ($bn), AGR (%), CAGR (%) by Segment, 2013-2024
Table 3.3 Market Shares (%) of MDx in the IVD Market, 2013, 2018& 2024
Table 4.1 The MDx Market: Revenues ($bn), Market Shares (%) by Segment, 2013
Table 4.2 The Global MDx Market Forecast: Revenue ($bn), AGR (%), CAGR (%) by Segment, 2013-2024
Table 4.3 The MDx Market: Revenue Shares (%) by Segment, 2013, 2018, 2024
Table 4.4 The Infectious Disease Testing Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2013-2024
Table 4.5 The Infectious Disease Testing Market: Revenues ($bn), Market Shares (%) by Disease, 2013
Table 4.6 Selected FDA-approved Molecular Diagnostics Test for HPV, 2014
Table 4.7 Selected FDA-approved Molecular Diagnostics Test for CT/NT, 2014
Table 4.8 Selected FDA-approved Molecular Diagnostics Test for HIV, 2014
Table 4.9 Selected FDA-approved Molecular Diagnostics Test for HCV, 2014
Table 4.10 Selected FDA-approved Molecular Diagnostics Test for HAIs, 2014
Table 4.11 The Oncology Testing Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2013-2024
Table 4.12 Examples of Clinically Relevant Cancer Biomarkers Tied With A Drug, 2014
Table 4.13 Selected List of FDA Approved MDx tests for Breast Cancer, 2014
Table 4.14 Selected List of FDA Approved MDx tests for Prostate Cancer, 2014
Table 4.15 Selected List of FDA Approved MDx tests for Colorectal Cancer, 2014
Table 4.16 The Blood Screening Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2013-2024
Table 4.17 The Genetic Testing Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2013-2024
Table 4.18 Selected Genetic Tests for Cystic Fibrosis on the Market, 2014
Table 4.19 Selected Genetic Tests for Factor V Leiden/Factor II Thrombophilia on the Market, 2014
Table 4.20 Key Alzheimer’s MDx Diagnostic Tests in Development, 2014
Table 4.21 The Tissue Typing Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2013-2024
Table 4.22 Selected HLA typing Kits on the Market, 2014
Table 5.1 The MDx Market: Revenue ($bn), Market Share (%) by Region, 2013
Table 5.2 The MDx Market: Revenue ($bn), AGR (%), CAGR (%) by Region, 2014-2024
Table 5.3 The MDx Market: Market Shares (%) by Regional Markets, 2013, 2018 and 2024
Table 5.4 The US MDx Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2013-2024
Table 5.5 The European MDx Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2013-2024
Table 5.6 The European MDx Market: Market Shares (%) by Country, 2013, 2018 and 2024
Table 5.7 The German MDx Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2013-2024
Table 5.8 The French MDx Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2013-2024
Table 5.9 The Italian MDx Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2013-2024
Table 5.10 The Spanish MDx Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2013-2024
Table 5.11 The UK MDx Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2013-2024
Table 5.12 The Other European MDx Market Forecast: Revenue ($bn), AGR (%), CAGR (%),
2013-2024
Table 5.13 The Japanese MDx Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2013-2024
Table 5.14 The Chinese MDx Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2013-2024
Table 5.15 The Brazilian MDx Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2013-2024
Table 5.16 The Russian MDx Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2013-2024
Table 5.17 The Indian MDx Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2013-2024
Table 5.18 The South Korean MDx Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2013-2024
Table 5.19 The Mexican MDx Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2013-2024
Table 5.20 The Rest of the World MDx Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2013-2024
Table 6.1 Roche Diagnostics: Revenue ($bn) and Revenue Share (%) by Business Area, 2013
Table 6.2 Roche Diagnostics: Revenue ($m), Revenue Shares (%) by Region, 2013
Table 6.3 Roche Diagnostics: Key Product Launches Planned for 2014
Table 6.4 Hologic: Revenue ($bn), Revenue Shares (%) by Segment, 2012-2013
Table 6.5 Qiagen: Revenue ($m), Revenue Shares (%) by Region, 2013
Table 6.6 Qiagen: Revenue ($m) and Revenue Shares (%) by Business Division, 2013
Table 6.7 Becton Dickinson: Revenue ($m), AGR (%) by Region, 2012-2013
Table 6.8 Becton Dickinson: Sales ($m), AGR (%) by Diagnostics Division, 2012-2013
Table 6.9 BioMérieux: Revenue ($m), AGR (%), 2010-2013
Table 6.10 BioMérieux: Revenue ($m), Revenue Change (%) by Region, 2012-2013
Table 6.11 BioMérieux: Revenue ($m), Revenue Share (%) by Region, 2013
Table 6.12 BioMérieux: Revenue ($m) by Technology, 2013
Table 6.13 Cepheid: Revenue ($m), Net Income ($m), 2010-2013
Table 6.14 Cepheid: Revenue ($m), AGR (%) by Industry, 2012-2013
Table 6.15 Cepheid: Revenue ($m), AGR (%) by Region and Industry, 2012-2013
Table 6.16 Agilent: Revenue ($bn), AGR (%), 2010-2013
Table 6.17 Agilent: Revenue ($bn), Revenue Share (%) by Business Segment, 2013
Table 6.18 Agilent Life Sciences and Diagnostics: Revenue ($bn) by Segment, 2011-2013
Table 7.1 SWOT Analysis of the Global MDx Market, 2014-2024
Table 9.1 MDx and Other In Vitro Diagnostics: World Revenue Forecast ($bn), 2013, 2018 and 2024

List of Figures
Figure 1.1 The Global Over 65 Population: Forecast (millions, AGR%), 2013-2024
Figure 1.2 Molecular Diagnostics: Overview of Submarkets
Figure 1.3 The South Korean MDx Market Forecast: Revenue ($bn), AGR (%), 2013-2024
Figure 3.1 World IVD Market: Revenues ($bn) by Segment, 2013
Figure 3.2 World IVD Market: Revenue Shares (%) by Segment, 2013
Figure 3.3 World IVD Market Forecast: Revenue ($bn), AGR (%) by Segment, 2013-2024
Figure 3.4 World MDx Market Share (%) in the IVD Market, 2018
Figure 3.5 World MDx Market Share (%) in the IVD Market, 2024
Figure 4.1 The MDx Market Shares (%) by Sector in the IVD Market, 2013
Figure 4.2 The MDx Market: Revenue ($bn) by Segment, 2013
Figure 4.3 The MDx Market: Market Shares (%) by Segment, 2013
Figure 4.4 The Global MDx Market Forecast: Revenue ($bn), AGR (%), 2013-2024
Figure 4.5 The MDx Market: Market Shares (%) by Segment, 2018
Figure 4.6 The MDx Market: Market Shares (%) by Segment, 2024
Figure 4.7 The Infectious Disease Testing Market Forecast: Revenue ($bn), AGR (%), 2013-2024
Figure 4.8 The Infectious Disease Testing Market: Revenue Shares (%) by Disease, 2013
Figure 4.9 The Oncology Testing Market Forecast: Revenue ($bn), AGR (%), 2013-2024
Figure 4.10 The Cancer Treatment Sequence and the Application of Molecular Diagnostics and Companion Diagnostics
Figure 4.11 The Blood Screening Market Forecast: Revenue ($bn), AGR (%), 2013-2024
Figure 4.12 The Genetic Testing Market Forecast: Revenue ($bn), AGR (%), 2013-2024
Figure 4.13 The Genetic Testing Market by Clinical Impact Area
Figure 4.14 The Tissue Typing Market Forecast: Revenue ($bn), AGR (%), 2013-2024
Figure 5.1 The MDx Market: Market Shares (%) by Region, 2013
Figure 5.2 The MDx Market: Revenue ($bn) by Region, 2013
Figure 5.3 The MDx Market: Market Shares (%) by Region, 2018
Figure 5.4 The MDx Market: Market Shares (%) by Region, 2024
Figure 5.5 The US MDx Market Forecast: Revenue ($bn), AGR (%), 2013-2024
Figure 5.6 The European MDx Market Forecast: Revenue ($bn) by Region, AGR (%), 2013-2024
Figure 5.7 The European MDx Market: Market Shares (%) by Country, 2013
Figure 5.8 The European MDx Market: Market Shares (%) by Country, 2018
Figure 5.9 The European MDx Market: Market Shares (%) by Country, 2024
Figure 5.10 The German MDx Market Forecast: Revenue ($bn), AGR (%), 2013-2024
Figure 5.11 The French MDx Market Forecast: Revenue ($bn), AGR (%), 2013-2024
Figure 5.12 The Italian MDx Market Forecast: Revenue ($bn), AGR (%), 2013-2024
Figure 5.13 The Spanish MDx Market Forecast: Revenue ($bn), AGR (%), 2013-2024
Figure 5.14 The UK MDx Market Forecast: Revenue ($bn), AGR (%), 2013-2024
Figure 5.15 The Other European MDx Market Forecast: Revenue ($bn), AGR (%), 2013-2024
Figure 5.16 The Japanese MDx Market Forecast: Revenue ($bn), AGR (%), 2013-2024
Figure 5.17 The Chinese MDx Market Forecast: Revenue ($bn), AGR (%), 2013-2024
Figure 5.18 The Brazilian MDx Market Forecast: Revenue ($bn), AGR (%), 2013-2024
Figure 5.19 The Russian MDx Market Forecast: Revenue ($bn), AGR (%), 2013-2024
Figure 5.20 The Indian MDx Market Forecast: Revenue ($bn), AGR (%), 2013-2024
Figure 5.21 The South Korean MDx Market Forecast: Revenue ($bn), AGR (%), 2013-2024
Figure 5.22 The Mexican MDx Market Forecast: Revenue ($bn), AGR (%), 2013-2024
Figure 5.23 The Rest of the World MDx Market Forecast: Revenue ($bn), AGR (%), 2013-2024
Figure 6.1 Roche Diagnostics: Revenues ($m) by Business Area, 2013
Figure 6.2 Roche Diagnostics: Revenue Share (%) by Business Area, 2013
Figure 6.3 Roche Diagnostics: Revenue Share (%) by Region, 2013
Figure 6.4 Hologic: Revenue ($bn) by Business Segment, 2013
Figure 6.5 Hologic: Product Pipeline, 2014
Figure 6.6 Qiagen: Revenue ($m), Net Income ($m) and Profit Margin (%), 2009-2013
Figure 6.7 Qiagen: Revenue Share (%) by Region, 2013
Figure 6.8 Becton Dickinson: Revenue ($m), Revenue Share (%) by Segment, 2013
Figure 6.9 Becton Dickinson: Revenue ($m) by Region, 2013
Figure 6.10 Becton Dickinson: Revenue Share (%) by Region, 2013
Figure 6.11 Becton Dickinson: Revenue Share (%) by Diagnostics Division, 2013
Figure 6.12 BioMérieux: Revenue ($m), AGR (%), 2010-2013
Figure 6.13 BioMérieux: Revenue ($m) by Region, 2013
Figure 6.14 BioMérieux: Revenue Share (%) by Region, 2013
Figure 6.15 Cepheid: Revenue ($m), Net Income ($m), 2010-2013
Figure 6.16 Cepheid: Revenue Share (%) by Industry, 2013
Figure 6.17 Cepheid: Revenue Share (%) by Region, 2013
Figure6.18 Agilent: Revenue ($bn), AGR (%),2010-2013
Figure 6.19 Agilent: Revenue Share (%) by Business Segment, 2013
Figure 6.20 Agilent Life Sciences and Diagnostics: Revenue Share (%) by Segment, 2013
Figure 7.1 MDx Market: Drivers and Restraints, 2014-2024
Figure 7.2 Porter’s Five Forces Analysis of the MDx Market, 2014-2024
Figure 9.1 MDx and Other In Vitro Diagnostics: World Revenue Forecast ($bn), 2013, 2018, and 2024
Figure 9.2 Molecular Diagnostics Market Forecast: AGRs (%) in India, China and Global Market, 2013-2024


【レポートのキーワード】

分子診断検査、感染症検査、癌検査、血液検査、遺伝子検査

★調査レポート[世界の分子診断市場:感染症検査、癌検査、血液検査、遺伝子検査] ( The Molecular Diagnostics (MDx) Market Forecast 2014-2024 : Opportunities for Leading Companies / VGAIN4120202) 販売に関する免責事項
[世界の分子診断市場:感染症検査、癌検査、血液検査、遺伝子検査] ( The Molecular Diagnostics (MDx) Market Forecast 2014-2024 : Opportunities for Leading Companies / VGAIN4120202) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆